U.S.				THE REAL PROPERTY.	yldan m
1,000	ING DATE CI 1/07/2001 5	LASS SUBCLA	SS GAU		MINER
**APPLICANTS:	MacKay Fa	abienne; Kalled	Susan;	1 MO (UM)	nghan
**CONTINUING DA' This application is a which is a 371 of PC which claims benefit and claims benefit of	CIP of 09/911,77 T/US00/01788 0 of 60/117,169 01 60/143,228 07/0	1/25/2000 1/25/1999 19/1999		VA TZB	
** FOREIGN APPLIC	ATIONS VERIFIE	ED:			
1		7			
PG-PUB DO NOT PU	виѕн 🗖	7	EIND 🔲	ATTORN'S V DOG	
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged 6	BLISH O	RESC I yes 🗆 no I yes 🗆 no		ATTORNEY DOC	KET NO
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged 6	BLISH O	RESC I yes 🗆 no I yes 🗆 no		00004 0004 5.55	KET NO
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met	BLISH O	RESC I yes 🗆 no I yes 🗆 no		00004 0004 5.55	KET NO 0 d treatment of
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged 6	BLISH O	RESC I yes 🗆 no I yes 🗆 no		08201.0024-01000 3-cell response and	KET NO 0 d treatment of
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged in TILE: BAFF, inhibitors autoimmune disorders	BLISH CONTROL	RESC I yes 🗆 no I yes 🗆 no		08201.0024-01000 3-cell response and	KET NO 0 d treatment of
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged 6	BLISH CONTROL	RESC		08201.0024-01000 3-cell response and USDEPT OF COMM PAT	KET NO 0 d treatment of
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged if ITLE: BAFF, inhibitors autoimmune disorders	Examiners's initials is thereof and the	RESC		08201.0024-01000 3-cell response and USDEPT OF COMM PAT	KET NO 0 d treatment of
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged is ITLE : BAFF, inhibitors autoimmune disorders	Examiners's initials is thereof and the	RESC		08201.0024-01000 3-cell response and US DEPT. OF COMM.PAT CLAIMS Total Claims	KET NO 0 d treatment of a TM-PTO-435L(Rev ALLOWED)
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged & TITLE: BAFF, inhibitors autoimmune disorders	Examiners's initials is thereof and the	RESC I yes in no I yes in the modern notation in use in the modern notation.		08201.0024-01000 3-cell response and USDEPT OF COMM PAT CLAIMS Total Claims	KET NO 0 d treatment of \$ TM-PTO-436L(Rev ALLOWED) Print Ca O.G.
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged is ITLE: BAFF, inhibitors autoimmune disorders	Examiners's initials is thereof and the	RESC I yes I no I yes I no ir use in the mod	dulation of E	O8201.0024-01000 3-cell response and USDEPT OF COMM PAT CLAIMS Total Claims DR/ Sheets Drug. Fi	KET NO 0 d treatment of 3 TM-PTO-436L(Rev ALLOWED Print Clai O.G
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged in TITLE: BAFF, inhibitors autoimmune disorders	Examiners's initials is thereof and the	RESC I yes I no I yes I no ir use in the mod	dulation of E	O8201.0024-01000 3-cell response and US DEPT. OF COMM.PAT CLAIMS Total Claims DRV Sheets Drwg. Fig.	KET NO 0 d treatment of \$ TM-PTO-435L(Rev ALLOWED) Print Clas 0.6 AWING pa. Drug. Print
PG-PUB DO NOT PU Foreign priority claimed 35 USC 119 conditions met Verified and Acknowledged in TITLE: BAFF, inhibitors autoimmune disorders DTICE OF ALLOWANCE MA ISSUE FEE mount Due Date Paid	Examiners's initials sthereof and the PR	RESC I yes in no I yes in the mode Ir use in the mode I was in the	dulation of E y Examiner SSUE	O8201.0024-01000 3-cell response and USDEPT OF COMM PAT CLAIMS Total Claims DR/ Sheets Drug. Fi	KET NO 0 d treatment of a TM-PTO-436L(Rev ALLOWED) Print Clai O.G AWING ps.Drug. Prin